MolDX Technical Assessment Process: DEX, Z-Codes & Dossiers

Securing Medicare Part B coverage for molecular diagnostics across states governed by the Molecular Diagnostic Services (MolDX) Program requires navigating a rigorous two-part pathway: cataloging the assay in the DEX Diagnostics Exchange to obtain a unique DEX Z-Code®, followed by submitting a comprehensive Technical Assessment (TA) dossier to Palmetto GBA. MolDX evaluates whether an assay meets Medicare's statutory "reasonable and necessary" standard under Title XVIII of the Social Security Act [§ 1862(a)(1)(A)] by scrutinizing three distinct tiers of evidence: analytical validity (AV), clinical validity (CV), and clinical utility (CU). Submissions stall most frequently when laboratories mistake Clinical Laboratory Improvement Amendments (CLIA) certification for coverage approval, omit granular run-level validation data, or fail to substantiate real-world clinical decision changes in peer-reviewed literature.

Key takeaways

• Z-Codes are identifiers, not coverage approvals: Registering a test in the DEX Diagnostics Exchange generates an administrative 5-character alphanumeric Z-Code, but Medicare reimbursement remains inactive until any required Technical Assessment receives a favorable determination.
• MolDX covers four Medicare Administrative Contractors (MACs): Palmetto GBA, Noridian Healthcare Solutions, CGS Administrators, and WPS Government Health Administrators administer MolDX policies across approximately 30 states; non-MolDX MACs (Novitas Solutions and First Coast Service Options) maintain independent Local Coverage Determinations (LCDs) and do not use the DEX system for Medicare claims adjudication.
• The evidentiary triad is non-negotiable: Submissions must demonstrate that the assay reliably measures the analyte (AV), correlates with a validated clinical phenotype or disease state (CV), and leads to actionable management decisions that improve patient health outcomes (CU).
• Standardized forms dictate dossier completeness: Submissions must anchor to Palmetto GBA form GEN-CQM-003 (TA Submission Checklist), GEN-PF-001 (Technical Assessment Summary Form), and relevant disease-specific performance worksheets.
• Claims must be suspended during active review: MolDX review cycles take a minimum of 60 calendar days; laboratories are instructed to hold Medicare Part B billing for the test during formal evaluation to avoid systematic claim denials.

Understanding the MolDX Program and Jurisdiction Scope

Established by Palmetto GBA in 2011, the MolDX Program evaluates molecular diagnostic technologies, establishes pricing, and authors clinical coverage policies under Medicare Part B. Rather than operating nationally, MolDX functions across four participating MACs:

• Palmetto GBA: Jurisdiction J (Alabama, Georgia, Tennessee) and Jurisdiction M (North Carolina, South Carolina, Virginia, West Virginia).
• Noridian Healthcare Solutions: Jurisdiction E (California, Hawaii, Nevada, American Samoa, Guam, Northern Mariana Islands) and Jurisdiction F (Alaska, Arizona, Idaho, Montana, North Dakota, Oregon, South Dakota, Utah, Washington, Wyoming).
• CGS Administrators: Jurisdiction 15 (Kentucky, Ohio).
• WPS Government Health Administrators: Jurisdiction 5 (Iowa, Kansas, Missouri, Nebraska) and Jurisdiction 8 (Indiana, Michigan).

Laboratories located in jurisdictions managed by Novitas Solutions (Jurisdictions H and L) or First Coast Service Options (Jurisdiction N) do not interface with MolDX for Medicare claims. However, developers operating across multiple sites must recognize that commercial payers—such as UnitedHealthcare and select Blue Cross Blue Shield plans—increasingly require DEX Z-Codes for claim tracking and prior authorization regardless of geographic location.

Step 1: DEX Diagnostics Exchange Registration and Z-Code Generation

The DEX Diagnostics Exchange serves as the central registry for molecular tests seeking reimbursement within MolDX jurisdictions.

1. Organization Registration: The performing laboratory establishes an organizational profile in the DEX registry, uploading CLIA licensure, College of American Pathologists (CAP) accreditation certificates, and facility details.
2. Test Entry and Characterization: The laboratory catalogs each proprietary assay. Required metadata includes the intended use statement, target genes/variants, methodology (e.g., next-generation sequencing, RT-qPCR, digital droplet PCR), specimen matrices, and expected Current Procedural Terminology (CPT) or Proprietary Laboratory Analyses (PLA) billing codes.
3. Z-Code Assignment: Once the entry is complete and submitted, DEX administrators review the record and assign a unique 5-character alphanumeric Z-Code. Administrative processing generally takes approximately two weeks.

A critical operational point: a Z-Code is solely a unique identifier. It connects the assay's method, intended use, and evidentiary record to Palmetto GBA's Master Edit File (MEF). Receiving a Z-Code does not indicate that the test is covered, medically necessary, or payable.

Step 2: Determining When a Technical Assessment Is Triggered

A Technical Assessment is not required for every molecular assay. Well-established single-analyte tests that fall squarely within narrow, non-algorithmic parameters defined by existing LCDs can often achieve coverage status through DEX registration alone. However, a formal TA is triggered when:

• A laboratory-developed test (LDT) seeks coverage under a specific MolDX LCD or Local Coverage Article (LCA) that explicitly mandates a TA before reimbursement is activated (e.g., solid tumor biomarker panels, minimal residual disease testing, pharmacogenomics).
• The assay uses novel chemistry, proprietary algorithms, or represents a multi-analyte assay with algorithmic analyses (MAAA).
• The assay targets an indication where the laboratory must independently demonstrate clinical validity and clinical utility because no established standard of care pathway exists.

If your assay requires a TA, its coverage status remains inactive in the DEX system and MEF until Palmetto GBA completes its review with an affirmative determination.

Step 3: Compiling the Evidentiary Dossier

MolDX reviews molecular assays through the lens of Title XVIII of the Social Security Act (§ 1862(a)(1)(A)), which prohibits Medicare payment for expenses that are not "reasonable and necessary for the diagnosis or treatment of illness or injury." To meet this statutory standard, CMS Program Integrity guidelines and MolDX instructions require comprehensive evidence across three interconnected pillars.

1. Analytical Validity (AV)

Analytical validity proves that an assay accurately, specifically, and reproducibly measures the targeted analyte or sequence variant. MolDX demands comprehensive standard operating procedures (SOPs), validation plans, and line-level data verifying:

• Limit of Detection (LoD): Empirically established across low-frequency variants or low-input nucleic acids using verified reference materials.
• Analytical Specificity: Exhaustive assessment of cross-reactivity and endogenous/exogenous interfering substances (e.g., hemoglobin, lipids, anticoagulants, fixatives).
• Precision: Within-run repeatability and between-run reproducibility evaluated across multiple operators, instrument runs, reagent lots, and days.
• Reportable and Reference Ranges: Validated boundaries for continuous and qualitative metrics.
• Specimen Stability and Integrity: Defined parameters for pre-analytical transport, temperature, time-to-fixation, ischemic intervals, and freeze-thaw cycles.
• Contamination Control: Quantitative evaluations of sample-to-sample carryover and environmental cross-contamination.

2. Clinical Validity (CV)

Clinical validity establishes that the assay reliably identifies, measures, or predicts the target clinical phenotype, disease state, or biological condition. Validation dossiers must include:

• Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) relative to an established orthogonal clinical reference standard.
• Positive Predictive Value (PPV) and Negative Predictive Value (NPV), modeled appropriately against real-world disease prevalence in the indicated population.
• Diagnostic sensitivity and specificity evaluated in a cohort directly representative of the intended patient population, using the intended clinical matrix (such as formalin-fixed paraffin-embedded [FFPE] tissue or whole blood), rather than relying solely on engineered cell lines or synthetic spike-ins.

3. Clinical Utility (CU)

Clinical utility is the most frequent point of failure in MolDX evaluations. The laboratory must prove that clinical decisions based on the assay's output directly result in improved patient health outcomes compared to clinical care delivered without the test.

Medicare coverage does not fund testing out of scientific interest; it funds assays that guide tangible clinical actions. The dossier must demonstrate that:

• The test results lead treating clinicians to select targeted therapies, adjust drug dosing, avoid ineffective or toxic treatments, or rule out unnecessary surgical interventions.
• These clinical management shifts result in measurable benefits relevant to the Medicare population, such as improved overall survival, extended progression-free survival, lower complication rates, or reduced hospitalizations.
• Evidence is published in peer-reviewed clinical literature rather than supported exclusively by internal case series, white papers, or expert opinions.

Step 4: Structuring and Submitting the TA Package

Submissions are sent directly to Palmetto GBA via email (MolDX@PalmettoGBA.com) following standardized forms and naming conventions:

• GEN-CQM-003 (Technical Assessment Submission Checklist): Mandatory for every TA submission. It acts as the index for your complete dossier, cross-referencing file locations for validation protocols, study results, and clinical literature.
• GEN-PF-001 (Technical Assessment Summary Form): Mandatory for novel tests or those establishing de novo clinical validity and utility.
• Specialty-Specific Performance Worksheets: Palmetto GBA maintains detailed worksheets for specific clinical spaces, such as SOM-PF-004 (Solid Tumors), SOM-PF-005 (Hematological Malignancies), MRD-PF-016 (Minimal Residual Disease), GER-PF-006 (Inherited Cancer), PGX-PF-007 (Pharmacogenomics), GER-PF-023 (Hereditary Thrombophilia), and MAA-PF-025 (MASLD/MASH Assays).

Laboratories must include fully articulated study protocols, statistical analysis plans, and line-level data tables. Summary slide decks, high-level marketing overviews, and unannotated data summaries do not meet submission standards.

During active review, tests entering a TA must not be billed to Medicare. Laboratories should hold claims until Palmetto GBA issues a final determination to avoid systematic administrative rejections. When designing complex analytical and clinical studies for multi-gene panels, working with specialized MolDX technical assessment consultants can ensure the evidentiary package meets these specific requirements before submission.

[DEX Registration] ──> [Z-Code Generated] ──> [TA Required?] 
                                                    │
                 ┌──────────────────────────────────┴──────────────────┐
                 ▼ (No)                                                ▼ (Yes)
       [Coverage Governed by LCD]                            [Compile Dossier]
                 │                                            • GEN-CQM-003 Checklist
                 ▼                                            • GEN-PF-001 Summary
       [Standard Claims Process]                              • Specialty Worksheets
                                                              • AV / CV / CU Studies
                                                                       │
                                                                       ▼
                                                             [Submit to Palmetto GBA]
                                                                       │
                                                                       ▼
                                                             [60-Day Initial Review]
                                                                       │
                                                ┌──────────────────────┴──────────────────────┐
                                                ▼ (Incomplete / Questions)                    ▼ (Complete)
                                     [Request for Add'l Info (RAI)]               [Favorable Determination]
                                                │                                             │
                                                └─────────────── Iterative Review ────────────┘
                                                                                              │
                                                                                              ▼
                                                                                  [MEF Updated / Claims Live]

Root Causes of MolDX Submission Stalls

A MolDX Technical Assessment takes a minimum of 60 calendar days from initial submission. However, reviewers often issue formal Requests for Additional Information (RAIs) that add months to the process. Six common procedural errors account for most delays:

1. Conflating CLIA Validation with MolDX Coverage Standards

Under 42 CFR § 493.1253, CLIA validation confirms that a laboratory can accurately perform a method within its facility. MolDX scrutinizes whether that test improves medical care under Medicare criteria. Passing a CLIA survey does not demonstrate clinical validity or clinical utility. Laboratories that structure submissions purely as CLIA analytical validation packages regularly fail to meet MolDX standards.

2. Omitting Raw Run Data and Granular Protocols

Submitting summary metrics (e.g., stating an LoD of 5% variant allele frequency without the underlying dilution series, reagent lots, and read depths) violates GEN-CQM-003 instructions. MolDX reviewers require the original standard operating procedures, validation protocols, and run-level datasets to assess how parameters were calculated. When analytical metrics lack this backing data, building a comprehensive analytical validation strategy is necessary to close the gaps.

3. Submitting Weak or Non-Existent Clinical Utility Data

A frequent pitfall is relying on anecdotal feedback, internal registries, or unvalidated surrogate endpoints. If clinicians can make the same patient management decision using established standard-of-care testing, the proposed test lacks unique clinical utility. Reviewers require peer-reviewed, published prospective or robust retrospective clinical studies demonstrating changed treatment decisions and patient benefits within the intended Medicare population.

4. Intended Use and Inclusion Discrepancies

A direct alignment must exist across four critical elements: the test description entered in DEX, the test ordering requisition, the clinical study cohorts, and the governing LCD. If a test is clinically validated only in metastatic castrate-resistant prostate cancer, but the DEX description claims utility across all solid tumors, reviewers will place the submission on hold for mismatched intended use.

5. Inadequate or Inappropriate Specimen Matrices

Validating an assay using commercial cell-line dilutions or purified genomic DNA cannot substitute for testing on the intended clinical specimen matrix. For example, testing archival FFPE tissue requires validating across varying fixation conditions, ischemic handling times, and low input concentrations. If the dossier relies on clean synthetic models, the laboratory will receive an RAI requiring matrix-specific re-validation.

6. Billing Code and Master Edit File Misalignment

Attempting to map an assay to an unlisted CPT code without validating that the code accurately reflects the procedure, or failing to request a dedicated PLA code when appropriate, can cause MEF conflicts. The reported billing code, the Z-Code assignment, and the laboratory test description must align precisely across all registry and billing systems. Aligning code selection with CPT and PLA coding requirements prevents billing errors and denials after technical review concludes.

Preparing a Successful Submission

Achieving timely MolDX coverage requires rigorous planning before completing any forms. Laboratories should verify that analytical protocols evaluate every intended matrix, confirm that clinical validity is proven against an accepted clinical reference method, and verify that peer-reviewed clinical utility studies clearly demonstrate changes in physician management and patient outcomes.

When technical documentation, registry data, and clinical evidence align with Palmetto GBA's evidentiary framework, the Technical Assessment pathway provides a predictable and structured route to reimbursement for molecular diagnostics across participating MAC jurisdictions.

How Priestly Consulting can help

Priestly Consulting provides strategic and scientific documentation support to help clinical laboratories and diagnostic developers navigate the MolDX lifecycle. From setting up DEX accounts and structuring Z-Code test registrations to assembling the analytical, clinical validity, and clinical utility dossiers required by GEN-CQM-003, our team works to resolve evidentiary gaps and avoid preventable review stalls. If you are preparing a new molecular test submission or working to resolve a MolDX Request for Additional Information, schedule a consultation to discuss your evidentiary strategy.